Description
This is a multi-center, open label, single group trial designed to evaluate the immunologic and general safety of long term use of Alphanate in patients diagnosed with severe Hemophilia A who have been previously treated with Factor VIII concentrates. Patient participation in this study will last for at least two years or a minimum of 50 exposure days, during which time the patient will be treated exclusively with Alphanate for prophylaxis, bleeding episodes, and surgery. Medical assesment would at a specified interval during the course of the study.